Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06607627 · ClinicalTrials.gov registry record · Phase 3
PK, PD, Safety, and Efficacy Study of Gefurulimab in Pediatric Patients With AChR+ Generalized Myasthenia Gravis
A Phase 3 study of Generalized Myasthenia Gravis and gMG, sponsored by Alexion Pharmaceuticals.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 12
- Enrollment target
- 13
- Study locations
NCT06607627: Recruiting Phase 3 study of Generalized Myasthenia Gravis and gMG, sponsored by Alexion Pharmaceuticals.
NCT06607627 is a Phase 3 study of Generalized Myasthenia Gravis and gMG that is actively recruiting participants, run by Alexion Pharmaceuticals. The registered enrollment target is 12 participants, below the 131-participant average among 26 other Generalized Myasthenia Gravis trials with a reported enrollment target (91% lower). The trial reports 13 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06607627, a Phase 3 study of Generalized Myasthenia Gravis and gMG, is actively recruiting participants, sponsored by Alexion Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 12 participants
- Enrollment target
- 13
- Study locations
Study Summary
The primary objective of this study is to assess the pharmacokinetics and pharmacodynamics of gefurulimab in pediatric participants with AChR+ gMG for the duration of the study.
Conditions Studied
Interventions
- COMBINATION_PRODUCT Gefurulimab
Study Locations (13)
Other
- Research Site - Joinville
- Research Site - Salvador
- Research Site - São José do Rio Preto
- Research Site - São Paulo
- Research Site - São Paulo
- Research Site - Saitama-Shi
- Research Site - Bydgoszcz
- Research Site - Lodz
- Research Site - Warsaw
- Research Site - New Taipei City
- Research Site - Taipei
District of Columbia
- Research Site - Washington D.C.
Virginia
- Research Site - Norfolk
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2024-11-13 |
| Est. Completion | 2029-01-23 |
| Phase | Phase 3 |
What NCT06607627 shows while recruiting
NCT06607627 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 131-participant average among 26 other Generalized Myasthenia Gravis trials with a reported enrollment target (91% lower).
The record links to 2 conditions, with Generalized Myasthenia Gravis appearing as the primary indexed condition, and to 1 intervention - of which Gefurulimab is the first listed.
NCT06607627 lists 13 locations in 3 states (Other, District of Columbia, Virginia).
Frequently Asked Questions
What is clinical trial NCT06607627 about?
NCT06607627 is a clinical study titled "PK, PD, Safety, and Efficacy Study of Gefurulimab in Pediatric Patients With AChR+ Generalized Myasthenia Gravis". The primary objective of this study is to assess the pharmacokinetics and pharmacodynamics of gefurulimab in pediatric participants with AChR+ gMG for the duration of the study.
What is the current status of trial NCT06607627?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 12 participants. The study started on 2024-11-13. Estimated completion is 2029-01-23.
What conditions does trial NCT06607627 study?
This clinical trial studies the following conditions: Generalized Myasthenia Gravis, gMG.
What interventions are being tested in trial NCT06607627?
The interventions under investigation include: Gefurulimab (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT06607627?
This trial is sponsored by Alexion Pharmaceuticals, which has 162 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06607627 being conducted?
This trial has 13 study locations across District of Columbia, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Generalized Myasthenia Gravis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06607627's enrollment target sits among peer trials
12 22nd of 26 higher than 1 of 26 other Generalized Myasthenia Gravis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Generalized Myasthenia Gravis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)
RECRUITING · Phase 3
-
A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)
RECRUITING · Phase 3
-
A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis
RECRUITING · Phase 3
-
A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 85 Years With gMG.
RECRUITING · Phase 3
-
Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis
RECRUITING · Phase 3
-
Open-Label Extension of Zilucoplan in Subjects With Generalized Myasthenia Gravis
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI